Research and Markets has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered: 1. Introduction 2. Critical Limb Ischemia Overview 3. Therapeutics Development 4. Pipeline Products for Critical Limb Ischemia - Overview 5. Pipeline Products for Critical Limb Ischemia - Comparative Analysis 6. Critical Limb Ischemia - Therapeutics under Development by Companies 7. Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes 8. Critical Limb Ischemia Products Glance 9. Late Stage Products 10. Clinical Stage Products 11. Early Stage Products 12. Critical Limb Ischemia - Products under Development by Companies 13. Critical Limb Ischemia - Products under Investigation by Universities/Institutes 14. Critical Limb Ischemia - Companies Involved in Therapeutics Development • AnGes MG, Inc. • Apceth GmbH & Co. KG • Athersys, Inc. • Caladrius Biosciences, Inc. • Cynata Therapeutics Limited • Hemostemix Ltd • Histocell S.L. • ID Pharma Co., Ltd. • IntelliCell BioSciences Inc. • Juventas Therapeutics, Inc. • Kasiak Research Private Limited • Kowa Company, Ltd. • Multi Gene Vascular Systems Ltd • Pharmicell Co., Ltd. • Pluristem Therapeutics Inc. • ReNeuron Group Plc • Stempeutics Research Private